Myeloid Therapeutics is an immunology company focused on combining biology insights with cutting-edge technologies to harness myeloid cells and eradicate cancer and other diseases. With broad clinical applications possible, the Company is presently advancing its cell therapy product candidates, derived from its ATAK™ platform technology, with initial applications in T cell lymphoma and a primed monocyte approach to treating glioblastoma. The ATAK™ platform is scalable to multiple treatment modalities and to other disease areas in collaboration. Myeloid expects to enter the clinic with its two lead programs in the first half of 2021. The company, having operations in Cambridge, MA, was founded by Ronald Vale and Siddhartha Mukherjee.